First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.

Abstract

Metastatic urothelial carcinoma is primarily a disease of the elderly, with a median overall survival of approximately 15 months. Cisplatin-based combination chemotherapy is standard first-line treatment for eligible patients, with carboplatin-based regimens used as an alternative for patients considered unfit to receive cisplatin. Prognostic models incorporating clinical risk factors have been validated, and molecular characteristics that predict for treatment response are under investigation. This review summarizes the current status of first-line treatment of metastatic urothelial carcinoma in platinum-eligible patients as well as prognostic and predictive models in this disease.

• Authors: Wassim Abida, Dean F Bajorin, Jonathan E Rosenberg
• Journal: Hematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 29 Issue 2 Pg. 319-28, ix-x (Apr 2015) ISSN: 1558-1977 [Electronic] United States
• PMID: 25836937 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Platinum

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Neoplasm Metastasis
• Platinum (administration & dosage)
• Prognosis
• Treatment Outcome
• Urinary Bladder Neoplasms (drug therapy, mortality, pathology)